WO1999047675A1 - Mu-1, member of the cytokine receptor family - Google Patents
Mu-1, member of the cytokine receptor family Download PDFInfo
- Publication number
- WO1999047675A1 WO1999047675A1 PCT/US1999/005854 US9905854W WO9947675A1 WO 1999047675 A1 WO1999047675 A1 WO 1999047675A1 US 9905854 W US9905854 W US 9905854W WO 9947675 A1 WO9947675 A1 WO 9947675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- seq
- amino acid
- nucleotide
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54728399A JP2001527423A (en) | 1998-03-17 | 1999-03-17 | MU-1 is a member of the cytokine receptor family |
AT99911454T ATE313626T1 (en) | 1998-03-17 | 1999-03-17 | MU-1, A MEMBER OF THE CYTOKINE RECEPTOR FAMILY |
EP99911454A EP0994947B1 (en) | 1998-03-17 | 1999-03-17 | Mu-1, member of the cytokine receptor family |
DE69929019T DE69929019T2 (en) | 1998-03-17 | 1999-03-17 | MU-1, A MEMBER OF THE CYTOKIN RECEPTOR FAMILY |
AU30093/99A AU758824B2 (en) | 1998-03-17 | 1999-03-17 | MU-1, member of the cytokine receptor family |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/040,005 US6057128A (en) | 1998-03-17 | 1998-03-17 | MU-1, member of the cytokine receptor family |
US09/040,005 | 1998-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999047675A1 true WO1999047675A1 (en) | 1999-09-23 |
Family
ID=21908554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/005854 WO1999047675A1 (en) | 1998-03-17 | 1999-03-17 | Mu-1, member of the cytokine receptor family |
Country Status (9)
Country | Link |
---|---|
US (3) | US6057128A (en) |
EP (4) | EP2228448A1 (en) |
JP (3) | JP2001527423A (en) |
AT (1) | ATE313626T1 (en) |
AU (1) | AU758824B2 (en) |
DE (1) | DE69929019T2 (en) |
DK (1) | DK0994947T3 (en) |
ES (1) | ES2253879T3 (en) |
WO (1) | WO1999047675A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000008152A1 (en) * | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
WO2000017235A3 (en) * | 1998-09-23 | 2000-07-20 | Zymogenetics Inc | Cytokine receptor zalpha11 |
EP1088831A1 (en) * | 1998-06-24 | 2001-04-04 | Chugai Research Institute for Molecular Medicine Inc. | Novel hemopoietin receptor proteins |
WO2001085792A2 (en) * | 2000-05-11 | 2001-11-15 | Genetics Institute, Llc. | Mu-1, member of the cytokine receptor family |
US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
US6777539B2 (en) | 2000-04-05 | 2004-08-17 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
US6803451B2 (en) | 1998-09-23 | 2004-10-12 | Zymogenetics, Inc. | Cytokine receptor zalpha11 polypeptides |
US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US7314623B2 (en) | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
JP2008094853A (en) * | 2001-10-04 | 2008-04-24 | Genetics Inst Llc | Method and composition for modulating interleukin-21 receptor activity |
US7495085B2 (en) | 2003-03-14 | 2009-02-24 | Wyeth | Antibodies against human or mouse IL-21 receptor |
US7705123B2 (en) | 1998-03-17 | 2010-04-27 | Genetics Institute, Llc | MU-1, member of the cytokine receptor family |
US7910105B2 (en) | 2005-04-14 | 2011-03-22 | Wyeth Llc | Methods for treating and preventing fibrosis |
CZ302921B6 (en) * | 1999-03-09 | 2012-01-18 | Zymogenetics, Inc. | Isolated polypeptide, fusion protein, polynucleotide, expression vector, host cell, antibody, process for preparing the protein, the antibody, propagation of hematopoietic cells, method of reducing proliferation of neoplastic B and T cells, method of |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004203069B2 (en) * | 1998-09-23 | 2008-06-12 | Zymogenetics Inc. | Cytokine Receptor Zalpha11 |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
WO2000069880A1 (en) * | 1999-05-18 | 2000-11-23 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
EP1531850B1 (en) * | 2002-06-07 | 2012-02-22 | ZymoGenetics, Inc. | Use of IL-21 and monoclonal antibody for treating solid cancers |
US20070092485A1 (en) * | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
CA2507817C (en) | 2002-12-13 | 2014-04-22 | Zymogenetics, Inc. | Il-21 production in prokaryotic hosts |
KR20060015482A (en) * | 2003-03-21 | 2006-02-17 | 와이어쓰 | Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
JP2007506789A (en) * | 2003-09-25 | 2007-03-22 | ザイモジェネティクス, インコーポレイテッド | Method for treating autoimmune disease using IL-21 |
PL1758610T3 (en) * | 2004-05-20 | 2012-11-30 | Zymogenetics Inc | Methods of treating cancer using il-21 and monoclonal antibody therapy |
US20070111941A1 (en) * | 2004-06-09 | 2007-05-17 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
JP2008508885A (en) * | 2004-08-05 | 2008-03-27 | ワイス | Neutralizing interleukin-21 receptor activity |
EP2805971A1 (en) * | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
CA2632218A1 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
CA2725154A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
PE20100141A1 (en) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | BINDING PROTEIN TO THE INTERLEUQUIN RECEPTOR 21 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0812913A2 (en) * | 1996-06-12 | 1997-12-17 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
WO1998031811A1 (en) * | 1997-01-16 | 1998-07-23 | Genetics Institute, Inc. | Member of the hematopoietin receptor superfamily |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
ES2092468T3 (en) * | 1988-01-22 | 1996-12-01 | Zymogenetics Inc | METHODS FOR PRODUCING SECRET RECEIVER ANALOGS. |
US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5216131A (en) * | 1989-02-23 | 1993-06-01 | Genentech, Inc. | Lymphocyte homing receptors |
US6406697B1 (en) * | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
FR2742156A1 (en) | 1995-12-06 | 1997-06-13 | Sanofi Sa | IL-13 RECEPTOR POLYPEPTIDE |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
AU2326097A (en) | 1996-03-13 | 1997-10-01 | Zymogenetics Inc. | Cytokine-receptor expressed in testis cells |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1997047741A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
AUPO224696A0 (en) | 1996-09-11 | 1996-10-03 | Amrad Operations Pty. Limited | A novel haemopoietin receptor and genetic sequences encoding same |
US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6509057B2 (en) * | 1998-04-01 | 2003-01-21 | Sumitomo Osaka Cement, Co., Ltd. | Antibacterial, antifungal or antialgal article and process for producing same |
CA2330547A1 (en) | 1998-06-24 | 1999-12-29 | Chugai Research Institute For Molecular Medicine, Inc. | Novel hemopoietin receptor proteins |
WO2000008152A1 (en) | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
US6803451B2 (en) * | 1998-09-23 | 2004-10-12 | Zymogenetics, Inc. | Cytokine receptor zalpha11 polypeptides |
IL142164A0 (en) | 1998-09-23 | 2002-03-10 | Zymogenetics Inc | Cytokine receptor zalpha11 |
WO2000027882A1 (en) | 1998-11-06 | 2000-05-18 | Smithkline Beecham Corporation | Hnovilr |
EP1881070B1 (en) | 1999-03-09 | 2012-10-03 | Zymogenetics, Inc. | Human cytokine as ligand of the zalpha receptor and uses thereof |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
WO2000069880A1 (en) | 1999-05-18 | 2000-11-23 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
WO2001036467A2 (en) | 1999-11-18 | 2001-05-25 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
JP2003535037A (en) | 1999-12-23 | 2003-11-25 | ザイモジェネティクス,インコーポレイティド | How to treat inflammation |
WO2001077171A2 (en) * | 2000-04-05 | 2001-10-18 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
DE10019727A1 (en) * | 2000-04-20 | 2001-10-25 | Alcatel Sa | Network server |
EP1353953B1 (en) | 2000-05-11 | 2006-11-29 | Genetics Institute, LLC | Mu-1, member of the cytokine receptor family |
JP2002157737A (en) * | 2000-05-12 | 2002-05-31 | Tdk Corp | Optical recording method and optical recording medium |
US6680563B2 (en) * | 2001-06-27 | 2004-01-20 | Thomson Licensing S.A. | Color picture tube having a low expansion tension mask attached to a higher expansion frame |
US6719302B2 (en) * | 2001-07-02 | 2004-04-13 | Vertex, Inc. | Symmetrical gasket for a pipe joint with increased surface contact |
ES2629395T3 (en) | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Methods and compositions to modulate the activity of interleukin-21 |
WO2003040313A2 (en) | 2001-11-05 | 2003-05-15 | Zymogenetics, Inc | Il-21 antagonists |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
CA2491320A1 (en) * | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
EP2184298A1 (en) | 2003-03-14 | 2010-05-12 | Wyeth a Corporation of the State of Delaware | Antibodies against human IL-21 receptor and uses therefor |
KR20060015482A (en) * | 2003-03-21 | 2006-02-17 | 와이어쓰 | Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
RU2006138704A (en) | 2004-05-19 | 2008-06-27 | Вайет (Us) | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
JP2008508885A (en) * | 2004-08-05 | 2008-03-27 | ワイス | Neutralizing interleukin-21 receptor activity |
GT200600148A (en) * | 2005-04-14 | 2006-11-22 | METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS | |
WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
CA2725154A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
PE20100141A1 (en) | 2008-05-23 | 2010-02-22 | Wyeth Corp | BINDING PROTEIN TO THE INTERLEUQUIN RECEPTOR 21 |
-
1998
- 1998-03-17 US US09/040,005 patent/US6057128A/en not_active Expired - Lifetime
-
1999
- 1999-03-17 WO PCT/US1999/005854 patent/WO1999047675A1/en active IP Right Grant
- 1999-03-17 ES ES99911454T patent/ES2253879T3/en not_active Expired - Lifetime
- 1999-03-17 DK DK99911454T patent/DK0994947T3/en active
- 1999-03-17 AT AT99911454T patent/ATE313626T1/en active
- 1999-03-17 EP EP10167168A patent/EP2228448A1/en not_active Withdrawn
- 1999-03-17 AU AU30093/99A patent/AU758824B2/en not_active Ceased
- 1999-03-17 EP EP05112423A patent/EP1688495A1/en not_active Withdrawn
- 1999-03-17 EP EP05112429A patent/EP1681348A1/en not_active Withdrawn
- 1999-03-17 DE DE69929019T patent/DE69929019T2/en not_active Expired - Lifetime
- 1999-03-17 EP EP99911454A patent/EP0994947B1/en not_active Expired - Lifetime
- 1999-03-17 JP JP54728399A patent/JP2001527423A/en not_active Withdrawn
-
2007
- 2007-12-17 US US11/957,891 patent/US7705123B2/en not_active Expired - Fee Related
-
2009
- 2009-10-02 JP JP2009230370A patent/JP2010057489A/en active Pending
-
2010
- 2010-01-28 US US12/695,485 patent/US7994292B2/en not_active Expired - Fee Related
-
2013
- 2013-04-25 JP JP2013093025A patent/JP2013188214A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0812913A2 (en) * | 1996-06-12 | 1997-12-17 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
WO1998031811A1 (en) * | 1997-01-16 | 1998-07-23 | Genetics Institute, Inc. | Member of the hematopoietin receptor superfamily |
Non-Patent Citations (3)
Title |
---|
BAZAN J. F.: "Structural design and molecular evolution of a cytokine receptor superfamily.", PROC. NATL. ACAD. SCI. U.S.A., vol. 87, 1990, pages 6934 - 6938, XP002111161 * |
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002111162, Database accession no. AC002303 * |
DUSANTER-FOURT I. ET AL.: "TRANSDUCTION DU SIGNAL PAR LES RECEPTEURS DE CYTOKINES", M/S MEDECINE SCIENCES, vol. 10, no. 8/9, 1 August 1994 (1994-08-01), pages 825 - 835, XP000611513 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7994292B2 (en) | 1998-03-17 | 2011-08-09 | Genetics Institute, Llc | MU-1, member of the cytokine receptor family |
US7705123B2 (en) | 1998-03-17 | 2010-04-27 | Genetics Institute, Llc | MU-1, member of the cytokine receptor family |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
EP1088831A1 (en) * | 1998-06-24 | 2001-04-04 | Chugai Research Institute for Molecular Medicine Inc. | Novel hemopoietin receptor proteins |
EP1088831A4 (en) * | 1998-06-24 | 2003-01-02 | Chugai Pharmaceutical Co Ltd | Novel hemopoietin receptor proteins |
WO2000008152A1 (en) * | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
EA014417B1 (en) * | 1998-09-23 | 2010-12-30 | Займодженетикс, Инк. | Expression vector comprising polynucleotide encoding human cytokine receptor zalpha11 or functional components thereof, cultured cells comprising the expression vector, method for producing zalpha11 polypeptide or functional components thereof, polypeptide produced by said method, antibody which binds to polypeptide and polynucleotide encoding polypeptide |
US7923212B2 (en) | 1998-09-23 | 2011-04-12 | Zymogenetics, Inc. | Antibodies to cytokine receptor zalpha11 |
US6692924B2 (en) | 1998-09-23 | 2004-02-17 | Zymogenetics, Inc. | Methods of using cytokine receptor zalpha11 to detect its ligands |
EP2105446B1 (en) * | 1998-09-23 | 2013-08-14 | ZymoGenetics, Inc. | Cytokine receptor zalpha11 |
US6803451B2 (en) | 1998-09-23 | 2004-10-12 | Zymogenetics, Inc. | Cytokine receptor zalpha11 polypeptides |
US8372602B2 (en) | 1998-09-23 | 2013-02-12 | Zymogenetics, Inc. | Methods for producing cytokine receptor ZALPHA11 |
US8110372B2 (en) * | 1998-09-23 | 2012-02-07 | Zymogenetics, Inc. | Methods for detecting modulators of cytokine receptor zalpha11 |
WO2000017235A3 (en) * | 1998-09-23 | 2000-07-20 | Zymogenetics Inc | Cytokine receptor zalpha11 |
US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
JP4704565B2 (en) * | 1998-09-23 | 2011-06-15 | ザイモジェネティクス, インコーポレイテッド | Cytokine receptor ZALPHA11 |
JP2002526062A (en) * | 1998-09-23 | 2002-08-20 | ザイモジェネティクス,インコーポレイティド | Cytokine receptor ZALPHA11 |
US7638286B2 (en) | 1998-09-23 | 2009-12-29 | Zymogenetics, Inc. | Antibodies to cytokine receptor zalpha11 |
US7411056B2 (en) | 1998-09-23 | 2008-08-12 | Zymogenetics, Inc. | Polynucleotides encoding cytokine receptor zalpha11 |
US7435550B2 (en) | 1998-09-23 | 2008-10-14 | Zymogenetics, Inc. | Methods of using cytokine receptor zalpha11 to detect its ligands |
CZ302921B6 (en) * | 1999-03-09 | 2012-01-18 | Zymogenetics, Inc. | Isolated polypeptide, fusion protein, polynucleotide, expression vector, host cell, antibody, process for preparing the protein, the antibody, propagation of hematopoietic cells, method of reducing proliferation of neoplastic B and T cells, method of |
EP1749888A3 (en) * | 2000-04-05 | 2007-03-14 | ZymoGenetics, Inc. | Soluble zalpha11 cytokine receptors |
US7629452B2 (en) | 2000-04-05 | 2009-12-08 | Zymogenetics, Inc. | Polynucleotides encoding soluble zalpha11 cytokine receptors |
US6777539B2 (en) | 2000-04-05 | 2004-08-17 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
US7189695B2 (en) | 2000-04-05 | 2007-03-13 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
US7763713B2 (en) | 2000-04-05 | 2010-07-27 | Zymogenetics, Inc. | Zalpha11 cytokine receptors |
JP2004500845A (en) * | 2000-05-11 | 2004-01-15 | ジェネティクス インスティテュート,エルエルシー | MU-1 is a member of the cytokine receptor family |
EP1787997A1 (en) * | 2000-05-11 | 2007-05-23 | Genetics Institute, LLC | MU-1, member of the cytokine receptor family |
WO2001085792A2 (en) * | 2000-05-11 | 2001-11-15 | Genetics Institute, Llc. | Mu-1, member of the cytokine receptor family |
JP2012061009A (en) * | 2000-05-11 | 2012-03-29 | Genetics Inst Llc | Mu-1, member of cytokine receptor family |
WO2001085792A3 (en) * | 2000-05-11 | 2003-08-21 | Inst Genetics Llc | Mu-1, member of the cytokine receptor family |
JP2008094853A (en) * | 2001-10-04 | 2008-04-24 | Genetics Inst Llc | Method and composition for modulating interleukin-21 receptor activity |
US7731946B2 (en) | 2002-07-15 | 2010-06-08 | Wyeth Llc | Methods and compositions for modulating T helper (TH) cell development and function |
US7314623B2 (en) | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
US7495085B2 (en) | 2003-03-14 | 2009-02-24 | Wyeth | Antibodies against human or mouse IL-21 receptor |
US8143385B2 (en) | 2003-03-14 | 2012-03-27 | Wyeth Llc | Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor |
US7910105B2 (en) | 2005-04-14 | 2011-03-22 | Wyeth Llc | Methods for treating and preventing fibrosis |
Also Published As
Publication number | Publication date |
---|---|
JP2010057489A (en) | 2010-03-18 |
EP0994947B1 (en) | 2005-12-21 |
AU758824B2 (en) | 2003-04-03 |
JP2013188214A (en) | 2013-09-26 |
US20100130729A1 (en) | 2010-05-27 |
DE69929019T2 (en) | 2006-08-03 |
US20080167241A1 (en) | 2008-07-10 |
EP1688495A1 (en) | 2006-08-09 |
EP1681348A1 (en) | 2006-07-19 |
JP2001527423A (en) | 2001-12-25 |
US7994292B2 (en) | 2011-08-09 |
ATE313626T1 (en) | 2006-01-15 |
DE69929019D1 (en) | 2006-01-26 |
DK0994947T3 (en) | 2006-04-18 |
AU3009399A (en) | 1999-10-11 |
US6057128A (en) | 2000-05-02 |
ES2253879T3 (en) | 2006-06-01 |
US7705123B2 (en) | 2010-04-27 |
EP0994947A1 (en) | 2000-04-26 |
EP2228448A1 (en) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0994947B1 (en) | Mu-1, member of the cytokine receptor family | |
US8048984B2 (en) | Human GIL-19/AE289 proteins | |
JP5763518B2 (en) | MU-1, a member of the cytokine receptor family | |
WO1998031811A1 (en) | Member of the hematopoietin receptor superfamily | |
US20030049798A1 (en) | MU-1, member of the cytokine receptor family | |
WO2000021990A1 (en) | SECRETED EXPRESSED SEQUENCE TAGS (sESTs) | |
AU2001263088A1 (en) | MU-1, member of the cytokine receptor family | |
WO1998040485A1 (en) | Human secreted protein, ba3.1, and polynucleotides encoding same | |
US20020039760A1 (en) | Polynucleotides encoding novel secreted proteins | |
AU2003208117B2 (en) | MU-1, member of the cytokine receptor family | |
AU769279B2 (en) | U4, a member of the hematopoietin receptor superfamily | |
US20020192779A1 (en) | Secreted protein, BA3.1, and polynucleotides encoding same | |
MXPA99010596A (en) | Mu-1, member of the cytokine receptor family | |
MXPA00009834A (en) | U4, a member of the hematopoietin receptor superfamily |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 547283 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/010596 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 30093/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999911454 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999911454 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 30093/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999911454 Country of ref document: EP |